Abstract PS3-11-25: Adjuvant ovarian function suppression (OFS) in HR+/HER2+ premenopausal breast cancer (BC) patients with pathologic complete response (pCR) or residual disease (RD) after neoadjuvant chemotherapy (NAC): a real-world study